Introducing DiaphOne Therapeutics: Developing small molecule antagonists

‍PRESS RELEASE

DiaphOne Therapeutics launched to develop small molecule antagonists for the treatment of diabetic nephropathy, neurodegeneration and other indications

‍

NLC Health Ventures launches DiaphOne Therapeutics, a preclinical stage biotech company, focused on the development of first-in-class small molecules for diabetic nephropathy, neurodegeneration (ALS and Alzheimer’s disease) and other indications.

‍

The company was founded by NLC Health Ventures to further develop and commercialize innovative work on RAGE antagonists from the labs of Ann Marie Shmidt, M.D. at  NYU Langone Health, in collaboration with NYU Technology Opportunities and Ventures’ Therapeutics Alliances program, and Alexander Shekhtman, Ph.D. at The University at Albany, State University of New York (SUNY).                                                                                 

‍

DiaphOne Therapeutics is developing first-in-class RAGE antagonists targeting the intracellular RAGE-DIAPH1 pathway. Compared to extracellular receptor approaches, these compounds provide increased efficacy and decreased redundancy, resulting in a targeted therapeutic effect halting disease progression through central mechanisms. The compounds have shown efficacy in preclinical models of diabetic nephropathy and ALS, making them a promising treatment for diabetic complications and neurodegeneration.

‍

DiaphOne Therapeutics is currently completing in vivo proof of concept studies with the identified lead candidate and is pursuing diabetic nephropathy as primary indication. The company will receive a pre-seed investment from The NLC Health Impact Fund to accelerate seed fundraising and support lead optimization to ultimately bring a curative treatment to patients.

‍

About DiaphOne Therapeutics

DiaphOne Therapeutics BV is a preclinical stage biotech company, focusing on the development of small molecule RAGE antagonists for the treatment of diabetic nephropathy, diabetic complications, neurodegeneration and other indications. The company is based in The Netherlands.

‍

More Information:

Lydia Kalafateli PhD, MBA, Entrepreneur in Residence, DiaphOne Therapeutics

Email: info@diaphonetx.com

Website: www.diaphonetx.com 

LinkedIn page: DiaphOne Therapeutics